We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genes Linked to Drug Resistance in Testicular Cancer

By LabMedica International staff writers
Posted on 03 Feb 2015
Several new genetic mutations have been revealed that could drive testicular cancer. More...
In addition, a gene has been identified, which may contribute to tumors becoming resistant to current treatments.

The main testicular germ cell tumor (TGCT) histologies are seminomas, which resemble undifferentiated primary germ cells, and non-seminomas, which show differing degrees of differentiation. Cure rates for TGCTs are generally high, due to the sensitivity of malignant testicular germ cells to platinum-based chemotherapies; however this is at the cost of an increased risk of metabolic syndrome, infertility and secondary cancer.

A team of scientists led by those at the Institute of Cancer Research (London, UK) used a genetic technique called whole-exome sequencing to examine tumor samples from 42 patients with undergoing testicular cancer treatment. Surgical specimens were snap frozen within 30 minutes of surgery and matched blood samples were collected at the time of surgery. Tumor samples were trimmed to remove surrounding normal tissue, and tumor cells were confirmed by histological assessment. Tumor and matched lymphocyte DNA were extracted by standard techniques.

Samples for whole-exome sequencing were quantified using Qubit technology (Invitrogen; Carlsbad, CA, USA) and sequencing libraries constructed from 50 ng of respective normal/tumor DNA. Library preparation was performed using 37 Mb Nextera Rapid Capture Exome kits (Illumina; San Diego, CA, USA), with enzymatic tagmentation, indexing polymerase chain reaction PCR, clean-up, pooling, target enrichment and post-capture PCR amplification/quality control performed in-house, following standardized protocols. Samples underwent paired-end sequencing using the Ilumina HiSeq2500 platform with a 100-bp read length.

The investigators uncovered a number of new chromosome duplications and other abnormalities that could contribute to the development of this cancer, as well as confirming a previous association with the V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog gene (KIT). Their study also found defective copies of a DNA repair gene called X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 2 (XRCC2) in a patient who had become resistant to platinum-based chemotherapy. They were able to verify the link between XRCC2 and platinum resistance by sequencing an additional sample from another platinum-resistant tumor.

Clare Turnbull, MD, PhD, the team leader, said, “Our study is the largest comprehensive sequencing study of testicular tumors published to date, describing their mutational profile in greater detail than has been possible using previous technologies. We have identified new potential driver mutations for this type of cancer, and provided new evidence of a link between mutations in the gene XRCC2 and platinum treatment-resistant tumors.” The study was published on January 22, 2015, in the journal Nature Communications.

Related Links:

The Institute of Cancer Research
Invitrogen 
Illumina



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.